

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/tcr-24-1374">https://dx.doi.org/10.21037/tcr-24-1374</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	In particular, we will share detailed data on the expression of OPN3 in triple-negative breast cancer tissue samples in relation to clinical parameters, which is rarely seen in previous studies.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the analysis methods may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in studies of breast cancer.
8	For what type of analysis or purpose?	Diagnostic biomarkers and therapeutic targets for predicting triple-negative breast cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address: <a href="mailto:lym852963@163.com">lym852963@163.com</a>
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.